{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:35:59Z","timestamp":1759412159072,"version":"3.41.2"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriasis has not been directly linked to a poor prognosis for COVID-19, yet immunomodulatory agents used for its management may lead to increased vulnerability to the dangerous complications of SARS-CoV-2 infection, as well as impair the effectiveness of the recently introduced vaccines. The three-dose antibody response trend and the safety of BNT162b2 mRNA vaccine in psoriasis patients treated with biologic drugs have remained under-researched.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Forty-five psoriatic patients on biologic treatment were enrolled to evaluate their humoral response to three doses of BNT162b2. IgG titers anti-SARS-CoV-2 spike protein were evaluated at baseline (day 0, first dose), after 3 weeks (second dose), four weeks post-second dose, at the time of the third dose administration and 4 weeks post-third dose. Seropositivity was defined as IgG \u226515 antibody-binding units (BAU)\/mL. Data on vaccine safety were also collected by interview at each visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A statistically significant increase in antibody titers was observed after each dose of vaccine compared with baseline, with no significant differences between patients and controls. Methotrexate used in combination with biologics has been shown to negatively influence the antibody response to the vaccine. On the contrary, increasing body mass index (BMI) positively influenced the antibody response. No adverse effects were reported, and no relapses of psoriasis were observed in the weeks following vaccine administration in our study population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data are largely consistent with the recent literature on this topic confirming the substantial efficacy and safety of BNT162b2 mRNA vaccine on psoriatic patients treated with biologics of different types and support the recommendation to perform additional doses in this specific subgroup of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.961904","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:51:55Z","timestamp":1662439915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics"],"prefix":"10.3389","volume":"9","author":[{"given":"Dario","family":"Graceffa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sperati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Spoletini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Lora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pontone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Pellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cristaudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e116077","DOI":"10.1371\/journal.pone.0116077","article-title":"Psoriasis and the risk of pneumonia: a population-based study","volume":"9","author":"Kao","year":"2014","journal-title":"PLoS ONE."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom","volume":"138","author":"Takeshita","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2020.05.035","article-title":"The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic","volume":"83","author":"Wan","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/archdermatol.2012.1401","article-title":"Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis","volume":"148","author":"Azfar","year":"2012","journal-title":"Arch Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tcm.2019.11.001","article-title":"Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model","volume":"30","author":"Aksentijevich","year":"2020","journal-title":"Trends Cardiovasc Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjd.20062","article-title":"Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study","volume":"185","author":"Yiu","year":"2021","journal-title":"Br J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jid.2021.02.276","article-title":"254 COVID-19 related outcomes in psoriasis psoriasis arthritis patients","volume":"141","author":"Raiker","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40257-020-00552-w","article-title":"Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: a cohort study from northeast Italy","volume":"21","author":"Piaserico","year":"2020","journal-title":"Am J Clin Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13475","DOI":"10.1111\/dth.13475","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jaad.2020.06.999","article-title":"Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy","volume":"83","author":"Holcomb","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/vaccines9050478","article-title":"Impact of inflammatory immune dysfunction in psoriasis patients at risk for COVID-19","volume":"9","author":"Yendo","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fphar.2020.01333","article-title":"Immunosuppressive drugs and COVID-19: a review","volume":"11","author":"Schoot","year":"2020","journal-title":"Front Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13404","DOI":"10.1111\/tid.13404","article-title":"SARS-CoV2 and immunosuppression: a double-edged sword","volume":"22","author":"Lai","year":"2020","journal-title":"Transpl Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-021-00349-0","article-title":"Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-CoV-2 vaccination strategies?","volume":"9","author":"Speeckaert","year":"2021","journal-title":"Drugs R D."},{"key":"B21","unstructured":"2020"},{"key":"B22","unstructured":"2021"},{"key":"B23","unstructured":"2021"},{"key":"B24","unstructured":"2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"T2B! Immunity against SARS-CoV-2 study group. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e15408","DOI":"10.1111\/dth.15408","article-title":"Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study","volume":"35","author":"Piros","year":"2022","journal-title":"Dermatol Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e001847","DOI":"10.1136\/rmdopen-2021-001847","article-title":"Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors","volume":"8","author":"Venerito","year":"2022","journal-title":"RMD Open."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1016\/S2665-9913(22)00096-0","article-title":"Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis","volume":"4","author":"Widdifield","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e15464","DOI":"10.1111\/dth.15464","article-title":"Generalized erythrodermic psoriasis triggered by vaccination against severe acute respiratory syndrome Coronavirus 2","volume":"20","author":"Tran","year":"2022","journal-title":"Dermatol Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e15444","DOI":"10.1111\/dth.15444","article-title":"case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine","volume":"13","author":"Frioui","year":"2022","journal-title":"Dermatol Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/08998280.2021.2003681","article-title":"Acute exacerbation of psoriasis after COVID-19 Pfizer vaccination","volume":"35","author":"Lopez","year":"2021","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e15368","DOI":"10.1111\/dth.15368","article-title":"Psoriasis exacerbation after COVID-19 vaccination in high-risk group: How to manage it?","volume":"35","author":"Kabbani","year":"2022","journal-title":"Dermatol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jdin.2021.11.004","article-title":"Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: a case report and review of the literature","volume":"6","author":"Phuan","year":"2022","journal-title":"JAAD Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.abd.2021.07.006","article-title":"Is there a link between guttate psoriasis and SARS-CoV-2? A series of three cases","volume":"97","author":"Braz\u00e3o","year":"2022","journal-title":"An Bras Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1111\/jdv.17965","article-title":"Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre","volume":"36","author":"Koumaki","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e15331","DOI":"10.1111\/dth.15331","article-title":"Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: a report of three cases","volume":"35","author":"Durmaz","year":"2022","journal-title":"Dermatol Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2021.11.016","article-title":"New onset and exacerbation of psoriasis after COVID-19 vaccination","volume":"19","author":"Wei","year":"2022","journal-title":"JAAD Case Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e15177","DOI":"10.1111\/dth.15177","article-title":"Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience","volume":"35","author":"Musumeci","year":"2022","journal-title":"Dermatol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/jdv.17690","article-title":"New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin?","volume":"36","author":"Pesqu\u00e9","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/ced.14723","article-title":"Young Dermatologists Italian Network, Damiani G. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast","volume":"46","author":"Pacifico","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/ced.14631","article-title":"COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers","volume":"46","author":"Damiani","year":"2021","journal-title":"Clin Exp Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1111\/jdv.17502","article-title":"New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after SARS-CoV-2 vaccination","volume":"35","author":"Quattrini","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1111\/jdv.17449","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e15055","DOI":"10.1111\/dth.15055","article-title":"Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor","volume":"6","author":"Mieczkowska","year":"2021","journal-title":"Dermatol Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"261","DOI":"10.34172\/hpp.2021.32","article-title":"A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report","volume":"11","author":"Onsun","year":"2021","journal-title":"Health Promot Perspect."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B57","unstructured":""},{"key":"B58","unstructured":"2022"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1111\/jdv.17861","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs","volume":"36","author":"Cristaudo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e01224","DOI":"10.1128\/JCM.01224-20","article-title":"Clinical and analytical performance of an automated serological test that identifies S1\/S2-neutralizing IgG in COVID-19 patients semiquantitatively","volume":"58","author":"Bonelli","year":"2020","journal-title":"J Clin Microbiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/sim.4200","article-title":"Comparing paired vs. non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples","volume":"30","author":"Austin","year":"2011","journal-title":"Stat Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1214\/08-STS254","article-title":"Jake bowers covariate balance in simple, stratified and clustered comparative studies","volume":"23","author":"Ben","year":"2008","journal-title":"Statist Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v030.i09","article-title":"CEM Coarsened exact matching software","volume":"30","author":"Iacus","year":"2009","journal-title":"J Stat Softw."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/pan\/mpr013","article-title":"Causal Inference without Balance checking: coarsened exact matching","volume":"20","author":"Iacus","year":"2011","journal-title":"Political Analysis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin Arthritis Rheum."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"9","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"B71","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use","volume":"12","author":"Brodmerkel","year":"2013","journal-title":"J Drugs Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.vaccine.2016.12.068","article-title":"Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine","volume":"35","author":"Kapetanovic","year":"2017"},{"key":"B73","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41366-022-01111-5","article-title":"Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood","volume":"7","author":"Muscogiuri","year":"2022","journal-title":"Int J Obes (Lond)."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e13128","DOI":"10.1111\/obr.13128","article-title":"Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships","volume":"21","author":"Popkin","year":"2020","journal-title":"Obes Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/ijo.2011.208","article-title":"Obesity is associated with impaired immune response to influenza vaccination in humans","volume":"36","author":"Sheridan","year":"2012","journal-title":"Int J Obes (Lond)."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1001\/jama.1985.03360220053027","article-title":"Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine","volume":"254","author":"Weber","year":"1985","journal-title":"JAMA."},{"key":"B80","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.eclinm.2021.100928","article-title":"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine","volume":"36","author":"Pellini","year":"2021","journal-title":"EClinicalMedicine."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.961904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:52:02Z","timestamp":1662439922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.961904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":80,"alternative-id":["10.3389\/fmed.2022.961904"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.961904","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"961904"}}